EMEA-002883-PIP03-23
Submitted by Anonymous (not verified) on 10 June 2025 - 13:49
EMEA-002883-PIP03-23
Annual reports and work programmes
Submitted by Anonymous (not verified) on 10 June 2025 - 13:42
Annual reports and work programmes
Annexes - 2024 annual report of the European Medicines Agency
Submitted by Anonymous (not verified) on 10 June 2025 - 13:41
Annexes - 2024 annual report of the European Medicines Agency
Annex 10 - 2024 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication
Submitted by Anonymous (not verified) on 10 June 2025 - 13:40
Annex 10 - 2024 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication
2024 annual report of the European Medicines Agency
Submitted by Anonymous (not verified) on 10 June 2025 - 13:38
2024 annual report of the European Medicines Agency
Human medicines European public assessment report (EPAR): Jyseleca, filgotinib, Date of authorisation: 24/09/2020, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 10 June 2025 - 13:25
Human medicines European public assessment report (EPAR): Jyseleca, filgotinib, Date of authorisation: 24/09/2020, Revision: 14, Status: Authorised
EMEA-003393-PIP01-23
Submitted by Anonymous (not verified) on 10 June 2025 - 12:49
EMEA-003393-PIP01-23
2024 annual report is published
Submitted by Anonymous (not verified) on 10 June 2025 - 12:48
2024 annual report is published
EMEA-003333-PIP01-22
Submitted by Anonymous (not verified) on 10 June 2025 - 12:44
EMEA-003333-PIP01-22
EMEA-003299-PIP01-22
Submitted by Anonymous (not verified) on 10 June 2025 - 12:33
EMEA-003299-PIP01-22